
    
      The primary objective is to evaluate if the addition of Tucidinostat to rituximab,
      cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) prolongs event-free
      survival (EFS) compared with R-CHOP alone in subjects with newly diagnosed MYC/BCL2
      Double-Expressor subtype of DLBCL selected by IHC and FISH.
    
  